From Reactive to Predictive: How Clinical Quality Intelligence Can Redefine Inspection Readiness in Clinical Trials
Clinical trial quality management still runs on reactive workflows - TMF gaps surface close to inspection, EDC anomalies get escalated late, and protocol deviations pile up without trial-level trending. With ICH E6(R3) now in force as the global GCP standard, that model is no longer defensible.
Whitepaper Scope:
This whitepaper lays out a practical path from point-in-time inspection prep to continuous, risk-based quality oversight. You walk away with the regulatory case for change, a five-module AI architecture for closing the gap, and a deployment model — Agilisium's FDX — for getting it into production and actually adopted, not just piloted.
What is inside
- The regulatory case: ICH E6(R3), FDA's AI guidance, and the RBQM adoption data driving the shift now
- The five structural failure points in clinical quality management today — from eTMF fragmentation to point-in-time inspection readiness
- ClinQC Studio's five integrated AI modules: eTMF classification, CDISC-aware anomaly detection, deviation clustering, inspection readiness simulation, and unified quality dashboarding
- A competitive lens on how ClinQC differs from point eTMF, RBQM, and EDC solutions
- Regulatory and standards alignment across ICH E6(R3), DIA TMF Reference Model, CDISC, 21 CFR Part 11, and EMA Annex 11/22
- An introduction to FDX — Forward Deployment Agents, Services, and Experts — and how it turns a pilot into a production system
Who should read this
- Clinical Quality Assurance leaders at CROs and Sponsors
- Clinical Data Management leads
- Regulatory Affairs and inspection readiness teams
- TMF operations and eTMF leads
- RBQM and clinical operations leadership
- Digital transformation and AI leaders in Life Sciences evaluating enterprise AI deployment models
What you will walk away with
- A clear view of what ICH E6(R3) actually requires operationally, and where most quality teams fall short today
- A five-module blueprint for moving from reactive reporting to predictive quality intelligence
- A framework for keeping human-in-the-loop oversight intact while reducing manual QC effort
- An understanding of how FDX closes the gap between AI pilots and AI in production
- A practical basis for evaluating your own trial portfolio's inspection readiness posture
This paper gives clinical quality, data management, and regulatory leaders a grounded look at what continuous, AI-augmented quality oversight looks like in practice - and a concrete model, through Agilisium's FDX, for getting there without another shelved pilot.
.jpg)
.webp)
.avif)
.avif)
